New Delhi, May 9 (PTI) Fair-trade regulator CCI on Tuesday said it has cleared Edelweiss Alternative Asset Advisors and ESOF III Investment Fund's subscription to certain compulsorily convertible debentures of Biocon Biologics Ltd.

The deal has been cleared under the green channel route.

Also Read | Go First Airline Says Will Respond to DGCA Notice in Due Course.

Edelweiss Alternative Asset Advisors is a Sebi-registered alternative asset advisor, while ESOF III Investment Fund is a Sebi-registered Alternative Investment Fund (AIF).

The proposed combination relates to Edelweiss Alternative Asset Advisors and ESOF III Investment Fund's proposal to subscribe to certain compulsorily convertible debentures issued by Biocon Biologics Ltd (BBL), according to CCI.

Also Read | Karnataka Assembly Elections 2023: Voter ID Card Lost? Here's a List of Alternative Documents You Can Use to Cast Your Vote.

BBL is a global biosimilar firm, engaged in the manufacturing and commercialisation of pharmaceutical formulations.

The Competition Commission of India (CCI) said it has approved the proposed deal.

"The parties' activities do not exhibit any horizontal, vertical, or complementary overlaps in any of the plausible relevant markets.

"Therefore, the proposed combination is being notified under the green channel route," according to an update on the CCI website.

Under the green channel route, a transaction which does not raise any risk of an appreciable adverse effect on competition is deemed to be approved on being intimated to the anti-trust regulator.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)